

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest
and Waiver under 18 U.S.C. § 208(b)(3)

Kenneth Saag, M.D.

Committee: Arthritis Drugs Advisory Committee

Meeting Date: April 12, 2007

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to the safety and efficacy of New Drug Application (NDA) 21-389/21-772, proposed trade name, Arcoxia (etoricoxib), a non-steroidal, anti-inflammatory, cyclooxygenase-2 enzyme (COX-2) inhibitor, manufactured by Merck & Company, Inc., for the proposed indication of the relief of the signs and symptoms of osteoarthritis, I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

Type of Interest	Nature	Magnitude
Unrelated Speaker's Bureau	Sponsor	From \$10,001 to \$50,000 per year
Unrelated Advisory Board	Sponsor	Less than \$10,001 per year
Unrelated Consulting	Competing Firm	Less than \$10,001 per year
Unrelated Consulting	Competing Firm	Less than \$10,001 per year

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waiver is not valid.

_____/s/_____
Signature of SGE

_____/3/6/07_____
Date